Can-Fite BioPharma: Progress on Phase IIa Study for Pancreatic Cancer
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is set to present significant progress regarding its Phase IIa study for pancreatic cancer at the upcoming BIO International Convention. This convention, known for showcasing advances in biotechnology, will take place in a vibrant setting where industry leaders gather to discuss innovations and partnerships.
Details of the Phase IIa Clinical Trial
The Phase IIa study targets patients diagnosed with advanced pancreatic adenocarcinoma who have not responded to standard treatments. This open-label trial evaluates the safety and efficacy of Namodenoson, Can-Fite's drug candidate. Administered orally at a dose of 25 mg twice daily, the study plans to enroll approximately 20 patients over defined treatment cycles.
The Role of Leading Experts
Prof. Salomon Stemmer, a distinguished oncologist based at the Davidoff Center, leads this critical research. His expertise and guidance are instrumental in navigating the study's clinical dynamics. Notably, Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), recognizing its potential in tackling this aggressive cancer type.
Significant Milestones Achieved
As the trial progresses, it is noteworthy that 50% of the patient cohort has already been enrolled. This accomplishment marks an essential step forward, indicating a favorable safety profile for Namodenoson. Dr. Sari Fishman, the Vice President of Business Development at Can-Fite, emphasizes the urgent need for safe treatment options in the advanced pancreatic cancer arena. This clinical trial represents a promising avenue for patients who have exhausted traditional therapies.
Engaging Partnerships at BIO 2025
Can-Fite anticipates substantial engagement with potential partners and collaborators at the BIO International Convention. The event serves not only as a platform for presenting scientific advancements but also as an opportunity to forge collaborations to drive clinical objectives forward.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. stands at the forefront of drug development in biotechnology, focusing on cancer and inflammatory diseases. The company has established a comprehensive portfolio, including promising candidates such as Piclidenoson for psoriasis and Namodenoson, also under examination for hepatocellular carcinoma (HCC). Recent advancements bolster the company’s innovative edge and aim to address multi-billion dollar market segments.
Prospects in Expanding Markets
With Namodenoson's potential extending beyond pancreatic cancer to include other cancers like colon and prostate cancers, Can-Fite is positioned to significantly impact oncology treatment paradigms. Furthermore, the company’s third candidate, CF602, showcases effectiveness in erectile dysfunction treatments and reinforces Can-Fite's commitment to pioneering various therapeutic avenues.
Contact Information
For inquiries, Can-Fite BioPharma can be reached through the following:
Motti Farbstein
+972-3-9241114
Frequently Asked Questions
What is the focus of Can-Fite's Phase IIa study?
The Phase IIa study evaluates Namodenoson for patients with advanced pancreatic adenocarcinoma who have not responded to standard treatments.
Who is leading the clinical trial?
Prof. Salomon Stemmer, a recognized oncologist at the Davidoff Center, is leading the clinical trial.
What milestones has Can-Fite achieved in the trial?
Approximately 50% of the planned patient cohort has been enrolled, indicating progress in the study.
What does Orphan Drug Designation mean for Namodenoson?
This designation by the FDA underscores Namodenoson’s potential for the treatment of pancreatic cancer and facilitates the drug's development process.
How can I learn more about the company’s developments?
For more information, visit Can-Fite's official website or reach out via email.
